Clinical Trials

Duality Biologics and BioNTech Highlight Interim Data from P-I/IIa Trial of BNT324/DB-1311 in Advanced Solid Tumors at ESMO Asia 2024

Duality Biologics and BioNTech Highlight Interim Data from P-I/IIa Trial of BNT324/DB-1311 in Advanced Solid Tumors at ESMO Asia 2...

Shots: The P-I/IIa study assessed BNT324 (B7-H3 targeting ADC) in heavily pretreat...

VivaVision Biotech Reports Topline Results from P-II Study of VVN461 for Post-Operative Inflammation Following Cataract Surgery

VivaVision Biotech Reports Topline Results from P-II Study of VVN461 for Post-Operative Inflammation Following Cataract Surgery

Shots: The P-II trial assessed VVN461 (1.0% & 0.5%) vs vehicle for post-catara...

Eli Lilly Reports Results from the P-IIIb (SURMOUNT-5) Trial of Zepbound (Tirzepatide) in Obese Adults

Eli Lilly Reports Results from the P-IIIb (SURMOUNT-5) Trial of Zepbound (Tirzepatide) in Obese Adults

Shots: Eli Lilly reported topline data from P-IIIb (

Everest Medicines Reports Results from the P-Ib/IIa Study of EVER001 to Treat Primary Membranous Nephropathy

Everest Medicines Reports Results from the P-Ib/IIa Study of EVER001 to Treat Primary Membranous Nephropathy

Shots: The P-Ib/IIa study assessed EVER001 (XNW1011) to treat patients (n=31) with...

InventisBio Reports Results from the P-II Trial of D-2570 to Treat Moderate to Severe Plaque Psoriasis

InventisBio Reports Results from the P-II Trial of D-2570 to Treat Moderate to Severe Plaque Psoriasis

Shots: InventisBio has reported the results from P-II study assessing the safety &...

Image